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Abstract:
It has been shown previously that  receptor agonists reveal potential antidepressant activity in experimental models. Moreover,
some data indicate  receptor contribution to stress-induced responses (e.g., conditioned fear stress in mice), though the mechanism
bywhichligandscanexerttheireffects,remainsunclear.Recentstudieshaveindicatedthatantidepressantdrugs(ADs)inhibitglu-
cocorticoid receptor (GR) function in vitro. The aim of the present study was to find out whether  receptor ligands are able to di-
rectly affect GR action. To this end, we evaluated the effect of  receptor agonists and antagonists on GR function in mouse
fibroblastcells(L929)stablytransfectedwithmousemammarytumorvirus-chloramphenicolacetyltransferase(MMTV-CAT)plas-
mid (LMCATcells). For this study, we chose SA4503, PRE 084, DTG (selective 1 or 1/2 receptor agonists) and BD 1047, SM 21,
rimcazole ( receptor antagonists). Fluvoxamine, the selective serotonin reuptake inhibitor with 1/2 receptor affinity, was used for
comparison.ItwasfoundthatSM21(at1,3,10and30M),BD1047(3,10and30M)rimcazole(10M),andfluvoxamine(at3,
10 and 30 M) significantly inhibited corticosterone-induced gene transcription, while DTG, SA4503 and PRE 084 remained inef-
fective. Thus, thereceptor agonists that predominantly showed antidepressant-like activity inbehavioral models, were without ef-
fect in this in vitro model. These results suggest that antidepressant-like activity of  receptor agonists is independent of
corticosterone-inducedgenetranscription.Therefore,theattenuationofGRfunctioninducedbyreceptorantagonistsremainsam-
biguous and requires further study.
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Introduction
The ability of antidepressant drugs (ADs) to interact
with  receptors in the nanomolar range appears to be
relevant to the mechanism of antidepressant action [5,
41]. The  receptors are classified into two subtypes,
1 and 2 receptors: the first was cloned from rodent
and human tissues while the second has not yet been
fully characterized [36, 40]. The 1 sites are particu-
larly abundant in the hippocampal formation and other
limbic areas (involved in cognition and emotion),
while the highest densities of 2 receptors were re-
vealed mostly in regions related to motor functions
(cerebellum, red nucleus, superior colliculus, various
cranial nerve nuclei, substantia nigra and striatum).
Although the precise mechanism underlying the func-
tional response of these receptors is still uncertain, it
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gic, dopaminergic and serotonergic neurotransmitter
systems [4, 8, 12, 13, 27].
Preclinical studies have shown that targeting  re-
ceptors alone is sufficient (but not requisite) to pro-
duce antidepressant-like actions. As shown previously,
 receptor agonists (e.g., igmesine, SA 4503, (+)-pent-
azocine, and recently UMB 23 and UMB 82) produce
anti-immobility effects in animal models of depres-
sion such as the forced-swimming or tail-suspension
tests [5, 41, 48]. Moreover, the high-affinity  recep-
tor agonist igmesine is promising as AD therapy for
humans (phase II clinical trials) [47]. It is believed
that  receptors represent an initial target (similarly to
monoamine transporters) in a cascade of events that
ultimately results in an antidepressant action.
In patients suffering from major depression, hyper-
activity of the hypothalamic-pituitary-adrenocortical
(HPA) axis is often observed, and has been implicated
in the pathophysiology of this disease [2, 21, 31].
Hitherto obtained data indicate that hyperactivity of
the HPA axis in major depression can be induced by
impairment of the feedback inhibition mechanism
[17, 33]. The synthetic glucocorticoid, dexametha-
sone, is less potent in lowering blood cortisol levels in
depressed patients, as compared to healthy subjects
[16, 19, 45]. Clinically effective AD therapy can cor-
rect dysfunction of the HPA axis [16, 18]. In contrast,
some recent clinical studies reveal that the inhibitors
of cortisol synthesis (metyrapone, ketoconazole, amino-
glutetimide) also show antidepressant effects [17, 30].
In HPA-hyperactive transgenic mice (with reduced
glucocorticoid receptor (GR) expression mainly in
neuronal tissue), behavioral changes resembling those
observed in depressed patients, such as impairments
in food consumption, sleep, learning and memory, are
observed [28, 35, 37].
As was demonstrated previously, ADs increase the
expression of GR in the CNS, enhance GR-mediated
feedback inhibition and thereby decrease cortisol/cor-
ticosterone levels. ADs also inhibit some corticoster-
one-evoked effects, as well as GR-mediated transcrip-
tion of some genes [6]. GRs are ligand-dependent
transcription factors, which bind to a specific DNA
sequence (glucocorticoid responsive element – GRE)
and regulate expression of many target genes involved
in neurotransmission, metabolism, neurodegenerative
processes and immune system activity.
The aim of the present study was to determine
whether  receptor ligands are able to directly affect
GR-mediated gene transcription. To this end we evalu-
ated the effects of SA 4503 and PRE 084 (the selec-
tive 1 receptor agonists), di-o-tolylguanidine (DTG,
1/2 receptor agonist), and BD 1047, SM 21 and rim-
cazole (the  receptor antagonists), on the corticoste-
rone-induced chloramphenicol acetyltransferase (CAT)
activity in mouse fibroblast cells stably transfected
with mouse mammary tumor virus (MMTV)-CAT
plasmid. Fluvoxamine, the selective serotonin reup-
take inhibitor with high affinity for 1/2 receptors,
was used for comparison.
Materials and Methods
Cell culture
Effects of these drugs on GR-mediated gene expression
were determined in mouse fibroblast cells (L929), sta-
bly transfected with mouse mammary tumor virus-
chloramphenicol acetyltransferase (MMTV-CAT) re-
porter plasmid (LMCAT cells). The LMCAT cell line
was generously provided by Dr. E.R. Sanchez (De-
partment of Pharmacology, Medical College of Ohio,
Toledo, OH, USA). The cells were grown in DMEM
(Gibco-BRL, USA) with a 10% heat-inactivated fetal
bovine serum (Gibco-BRL, USA) and 0.02% Gene-
ticin (Gibco-BRL, USA) at 37°C, in a 5% CO2/95%
air atmosphere.
Drug treatments
The LMCAT cells (final confluency 80%) were treated
for five days with vehicle, N-[2-(3,4-dichlorophenyl)-
ethyl]-N-methyl-2-(dimethylamino)ethylamine (BD 1047,
Tocris Cookson Ltd., UK), 1,3-Di-o-tolylguanidine
(DTG, Research Biochemicals Int., USA), fluvoxam-
ine maleate (Tocris Cookson Ltd., UK), 2-(4-morpho-
linoethyl)-1-phenylcyclohexane-1-carboxylate hydro-
chloride (PRE 084, Tocris Cookson Ltd., UK), rimca-
zole dihydrochloride (Research Biochemicals Int.,
USA), 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-
piperazine dihydrochloride (SA4503, Santen Pharma-
ceutical Co. Ltd., Japan), (±)-tropanyl-2-(4-chlorophen-
oxy)butanoate maleate (SM 21, Tocris Cookson Ltd,
UK). The drugs were dissolved in water, except for
DTG which was dissolved in a small amount of etha-
nol, followed by dilution in the medium (the final
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cultures were supplemented with the same amount of
an appropriate vehicle. All drugs were added at final
concentrations of 1, 3, 10 and 30 M. The medium
and drugs were changed once over the course of
a 5-day culture. Gene transcription was stimulated by
adding 1 M corticosterone for 2 h before harvesting
cells.
Chloramphenicol acetyltransferase (CAT)
activity assay
CAT activity was determined as described previously
[3, 34]. Cell lysates were prepared by a freeze/thaw
procedure. To determine CAT activity, aliquots of
lysate (after heating at 60°C for 10 min) were incu-
bated in 0.25 M Tris-HCl buffer (pH = 7.8) with 0.25 Ci
D-threo-[dichloroacetyl-1-14C]-chloramphenicol and
0.2 mM n-butyryl coenzyme A at 37°C for 1 h. The
butyrylated forms of chloramphenicol (in direct pro-
portion to CAT gene expression) were extracted twice
with xylene, washed with 0.25 M Tris-HCl buffer; ra-
dioactivity was measured in a -counter (Beckmann
LS 335 liquid scintillation counter). The results are
presented as dpm of a butyrylated fraction of chlo-
ramphenicol per 10 g of protein per1ho fincuba-
tion. The protein concentration in cell lysates was de-
termined by the Lowry method [22].
Statistical analysis
The data are presented as the mean ± SEM of four to
five independent experiments (in duplicate wells).
The significance of differences between the means
was evaluated by Duncan’s test following one-way
analysis of variance.
Results
Addition of corticosterone at a concentration of 1 M
for 2 h increased CAT activity about 35-fold. As was
described previously, the effect of corticosterone was
completely blocked by addition of 10 M RU 38486,
a specific antagonist of the type II GR, confirming in-
volvement of the GR in this response [7].
None of the drugs examined affected the low base-
line levels of non-stimulated CAT activity (data not
shown). The lowest concentration of DTG (1 M)
slightly, but significantly, increased corticosterone-
induced reporter gene transcription [F (4, 31) = 2.797;
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Fig. 1. The effect of  receptor agonists, SA 4503 (A), PRE 084 (B)
and DTG (C) on corticosterone (1 µM, 2 h)-induced CAT activity in
LMCAT cells. SA 4503, PRE 084 and DTG were used at concentra-
tions of 1, 3, 10 and 30 µM for 5 days. Corticosterone (1 µM) was
added 2 h before harvesting the cells for assays of CAT enzyme ac-
tivity. The data are presented as the means ± SEM (% of control). The
significance of differences between the means was evaluated by
Duncan’s test following a one-way analysis of variance (* p < 0.05 vs.
respective control)p < 0.05] (Fig. 1C). Treatment of cells with  receptor
agonists – SA 4503 [F (4, 30) = 0.357], PRE 084
[F (4, 17) = 2.352] and higher doses of DTG (3, 10
and 30 M) failed to affect corticosterone-induced
CAT activity (Fig. 1A–C). BD 1047 (3, 10 and 30 but
not 1 M) (Fig. 2A) and rimcazole at 10 M (Fig. 2B)
inhibited corticosterone-induced gene transcription
[F(4, 25) = 5 9.916; p < 0.001 and F(3, 25) = 10.748;
p < 0.001, respectively]. The lower concentrations of
rimcazole were ineffective but higher doses induced
neurotoxic effects. SM 21 (1–30 M) decreased
corticosterone-induced CAT activity in a concentra-
tion-dependent manner [F(4, 31) = 25.12; p < 0.001)
(Fig. 2C). Fluvoxamine, used for comparison, signifi-
cantly inhibited corticosterone-induced gene tran-
scription at concentrations of 3, 10 and 30 M (its
lowest concentration was inactive) [F(4, 27) = 14.457;
p < 0.001] (Fig. 3).
Discussion
According to Su and Hayashi [43], 1 receptors are
endoplasmic reticular proteins that, when stimulated
by ligands, can translocate and thereby increase
[Ca2+]i by enhancing IP3 receptor signaling at the en-
doplasmic reticulum, via removal of ankyrin (an in-
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Fig. 2. The effect of  receptor antagonists: BD 1047 (A), rimcazole
(B),S M2 1(C) on corticosterone (1 µM)-induced CAT activity in
LMCAT cells. BD 1047, rimcazole and SM 21 were used at concen-
trations of 1, 3, 10 and 30 µM for 5 days. Corticosterone (1 µM) was
added 2 h before harvesting the cells for assays of CAT enzyme ac-
tivity. The data are presented as the mean ± SEM (% of control). The
significance of differences between the means was evaluated by
Duncan’s test following a one-way analysis of variance (* p < 0.05 vs.
respective control)
Fig. 3. The effect of fluvoxamine on corticosterone (1 µM)-induced
CAT activity in LMCAT cells. Fluvoxamine was used at concentrations
of 1, 3, 10 and 30 µM for 5 days. Corticosterone (1 µM) was added 2 h
before harvesting the cells for assays of CAT enzyme activity. The data
are presented as the mean ± SEM (% of control). The significance of dif-
ferences between the means was evaluated by Duncan’s test following
a one-way analysis of variance (* p < 0.05 vs. respective control)hibitory cytoskeletal adaptor protein) from the IP3
receptor. It has been hypothesized that  receptors
represent an initial target in a cascade of events that
ultimately results in an antidepressant effect. Al-
though the mechanisms underlying the ability of  re-
ceptor ligands (agonists) to produce antidepressant-
like actions have yet to be fully elucidated, results
suggest that  receptor agonists stimulate a variety of
neural adaptations in the central nervous system that
are relevant to antidepressant action. For example, it
has been shown recently that 1 receptors up-regulate
the release of brain-derived neurotrophic factor
(BDNF) [20]. The role of BDNF/TrkB signaling is
proposed as one of the possible mechanisms underly-
ing the therapeutic effect of ADs [e.g., 20]. Repeated
treatments with some ADs that are 1 receptor ago-
nists (e.g., fluvoxamine, used for comparison in this
study) significantly potentiate the BDNF-triggered
glutamate release in cultured cortical neurons through
1 receptor-mediated action (by enhancing the PLC-/
IP3/Ca2+ signaling pathway) [49]. Su and co-workers
report that some ADs showing affinity to 1 receptors
(e.g., fluvoxamine) enhanced nerve growth factor
(NGF)-induced neurite sprouting in PC12 cells [44].
The potentiation of BDNF-triggered glutamate re-
lease by fluvoxamine and SA4503 (a 1 receptor ago-
nist) was blocked by NE-100 (the 1 receptor antago-
nist), suggesting a role for 1 receptors in blocking
the enhancement of NGF-induced neurite outgrowth.
Likewise, these results indicated that interaction with
IP3 receptors, PLC-, PI3K, P38MAPK, JNK, and
Ras/Raf/MAPK signaling pathways are involved in
the mechanisms of action for the abovementioned
1 receptor ligands [32]. Indeed, it is accepted that the
physiological consequences of 1 receptor activation
are intracellular regulation of Ca2+ mobilization and
activation of PLC and protein kinase C (PKC) path-
ways [14, 29].
Since glucocorticoids at high concentration (stress)
evoke changes characteristic of depression in experi-
mental conditions, inhibition of GR function may be
connected with the therapeutic action of ADs. It was
shown that ADs (including imipramine, desipramine,
amitriptyline, fluoxetine, mianserin and tianeptine)
inhibited corticosterone-induced gene transcription in
a concentration- and time-dependent manner. More-
over, imipramine decreases binding of the corticoster-
one-receptor complex to DNA [7]. This inhibitory ef-
fect of imipramine depends partly on the PLC/PKC
pathway. Subsequent studies confirmed this assump-
tion by showing that imipramine inhibited PKC activ-
ity in LMCAT cells [1]. In conclusion, studies on the
mechanism of antidepressant action on GR function
revealed that PKC plays a key role in this phenome-
non.
The results obtained in this paper indicate that 1
receptor agonists SA 4503 and PRE 084 failed to af-
fect corticosterone-induced gene transcription. DTG
(1/2 receptor agonist) slightly increased the effect
of corticosterone on GR-mediated gene transcription
at the lowest concentration investigated. Two out of
three  agonists, DTG and SA 4503, exerted anti-
depressant-like activity in behavioral models (e.g.,
forced swim test or tail suspension test in rats and
mice). PRE 084 fails to affect the duration of immo-
bility in normal mice, but reduces the period of immo-
bility in adrenalectomized/castrated (AdX/CX) mice.
The augmented effect of PRE 084 in AdX/CX mice
was fully blocked by BD 1047 [46]. The antidepres-
sant-like activity of fluvoxamine was shown in mice
subjected to the forced-swim test [e.g., 48]. Surpris-
ingly, none of the 1 receptor agonists under study de-
crease the CAT activity induced by a high (stress)
concentration (1 M) of corticosterone. In contrast,
inhibitory activity (concentration-dependently) was
found for BD 1047, rimcazole and SM 21, and
fluvoxamine. As was mentioned above, BD 1047 is
accepted as 1-, while SM 21 is a 2-receptor antago-
nist [11, 23, 24, 42]. Rimcazole has been recognized
as an 1 antagonist but its affinity to  receptors is
rather low [10, 39]. Interestingly, rimcazole was the
first selective  ligand to be subjected to clinical trial
as a potential antipsychotic drug. It was found to im-
prove negative symptoms but exacerbate acute posi-
tive symptoms; however, subsequent clinical studies
were stopped [15]. In the present study, the neurotoxic
effect of rimcazole was observed at its higher concen-
trations. It is worth mentioning that the newly synthe-
sized  ligands, e.g., BD 1047, show much higher af-
finity for 1 vs. 2 receptors, in comparison to previ-
ously studied  ligands which were not selective for
1/2 sites.
There is no apparent correlation between the affin-
ity of ligands for 1 receptors and their inhibitory ef-
fect on corticosterone-induced CAT activity. For ex-
ample, SA 4503, with affinity to the 1 receptor com-
parable to that of fluvoxamine (IC50 = 17.4 nM and
13 nM, respectively) [26, 38], was ineffective in our
study. Rimcazole, having relatively low affinity to 1
receptor (IC50 = 520 nM), [39] induced the decrease
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mediated gene transcription. In addition, SA4503 is
defined as an 1 receptor agonist, while rimcazole
is defined as an antagonist. SM 21, described as an
2- receptor preferring antagonist (Ki for 1 receptor
= 1050 nM, for 2 = 145 nM) [25], inhibited cortico-
sterone-induced CAT activity in LMCAT cells in
a concentration-dependent manner.
 Receptor ligands capable of affecting GR-induced
gene transcription can act on different processes re-
lated to GR action, e.g., the binding of hormones with
receptors, dissociations of the steroid-receptor com-
plex from other cytosol proteins, translocation of the
hormone-GR complex from the cytoplasm to the nu-
cleus, phosphorylation of GR, binding to DNA, and
modulation of the transcription complex. Notably, the
action of  ligands on GR-mediated gene transcrip-
tion was studied in a fibroblast cell line, so it is un-
known if similar mechanisms characterize the process
in neurons. Nonetheless, it seems questionable that
“antidepressant-like” activity of  ligands, observed in
behavioral studies, could be directly connected with
GR function. The decrease in glucocorticoid-mediated
gene transcription produced by  receptor antagonists
may be related to their direct inhibition of PKC activ-
ity, while DTG may activate that enzyme.
Further studies are required to elucidate whether the
inhibition of corticosterone-induced CAT activity is
a common feature of  receptor antagonists or rather is
related to pharmacology unique to each compound,
thus independent of 1 receptor antagonistic activity.
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